GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Ar | multiple interactions | EXP | | 6480464 | CTD | bicalutamide binds to and results in decreased activity of AR protein; bicalutamide inhibits the reaction [[Testosterone binds to AR protein] inhibits the reaction [Dexamethasone results in increased expression of DDIT4 mRNA]] | PMID:20032058 | Ar | affects binding | ISO | AR (Homo sapiens) | 6480464 | CTD | [bicalutamide binds to AR protein] which binds to KLK3 promoter; bicalutamide binds to AR protein | PMID:12376534 PMID:15308689 PMID:15336702 | Ar | affects localization | ISO | AR (Homo sapiens) | 6480464 | CTD | bicalutamide affects the localization of AR protein | PMID:17606915 PMID:21308717 | Ar | affects response to substance | ISO | AR (Homo sapiens) | 6480464 | CTD | AR protein affects the susceptibility to bicalutamide | PMID:16015592 | Ar | decreases activity | ISO | AR (Homo sapiens) | 6480464 | CTD | bicalutamide results in decreased activity of AR protein | PMID:18776922 PMID:19131511 PMID:20729295 PMID:28757136 | Ar | decreases expression | ISO | Ar (Mus musculus) | 6480464 | CTD | bicalutamide results in decreased expression of AR protein | PMID:19587329 | Ar | decreases expression | ISO | AR (Homo sapiens) | 6480464 | CTD | bicalutamide results in decreased expression of AR; bicalutamide results in decreased expression of AR mRNA | PMID:11845989 PMID:15638997 PMID:29462692 | Ar | decreases response to substance | ISO | AR (Homo sapiens) | 6480464 | CTD | AR gene mutant form results in decreased susceptibility to bicalutamide; AR protein alternative form results in decreased susceptibility to bicalutamide | PMID:16015592 PMID:28500234 | Ar | increases expression | ISO | AR (Homo sapiens) | 6480464 | CTD | bicalutamide results in increased expression of AR; bicalutamide results in increased expression of AR protein | PMID:11845989 PMID:17723170 | Ar | multiple interactions | ISO | Ar (Mus musculus) | 6480464 | CTD | bicalutamide results in increased localization of and results in increased activity of AR protein | PMID:12015321 | Ar | multiple interactions | ISO | AR (Homo sapiens) | 6480464 | CTD | [Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to bicalutamide; [bicalutamide binds to and results in decreased activity of AR protein] inhibits the reaction [Dehydroepiandrosterone results in decreased expression of CYP1A2 mRNA]; [bicalutamide co-treated with Testosterone] affects the expression of and results in decreased activity of AR protein; [bicalutamide results in decreased susceptibility to bicalutamide] which results in increased expression of and affects the localization of AR protein alternative form; [bicalutamide results in decreased susceptibility to bicalutamide] which results in increased expression of AR mRNA; [bicalutamide results in decreased susceptibility to bicalutamide] which results in increased expression of AR mRNA alternative form; [bicalutamide results in decreased susceptibility to bicalutamide] which results in increased expression of AR protein; [Dihydrotestosterone co-treated with bicalutamide] promotes the reaction [AR protein binds to PHB1 protein]; [Dihydrotestosterone co-treated with bicalutamide] promotes the reaction [AR protein binds to SMARCA4 protein]; [Goserelin co-treated with bicalutamide] results in decreased expression of AR protein; [Goserelin co-treated with Dutasteride co-treated with bicalutamide co-treated with Ketoconazole] results in decreased expression of AR protein; [Goserelin co-treated with Dutasteride co-treated with bicalutamide] results in decreased expression of AR protein; AR protein promotes the reaction [bicalutamide promotes the reaction [PHB1 protein binds to KLK3 promoter]]; bicalutamide affects the reaction [beta-hexachlorocyclohexane affects the expression of AR protein]; bicalutamide affects the reaction [Testosterone affects the expression of AR protein]; bicalutamide binds to and affects the localization of and affects the activity of AR protein; bicalutamide binds to and results in decreased activity of AR protein; bicalutamide binds to and results in increased activity of AR protein mutant form; bicalutamide inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; bicalutamide inhibits the reaction [[Dihydrotestosterone binds to and results in increased activity of AR protein] which results in increased expression of KLK3 protein]; bicalutamide inhibits the reaction [[Metribolone binds to and results in increased activity of AR protein] which results in increased expression of KLK3 protein]; bicalutamide inhibits the reaction [alpha-naphthoflavone inhibits the reaction [Particulate Matter analog inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]]]; bicalutamide inhibits the reaction [alpha-naphthoflavone inhibits the reaction [Vehicle Emissions analog inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]]]; bicalutamide inhibits the reaction [AR protein alternative form binds to KLK3 promoter]; bicalutamide inhibits the reaction [AR protein alternative form promotes the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]]; bicalutamide inhibits the reaction [AR protein binds to KLK3 promoter]; bicalutamide inhibits the reaction [AR protein binds to NCOA1 protein]; bicalutamide inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]; bicalutamide inhibits the reaction [Cadmium Chloride results in decreased expression of AR mRNA]; bicalutamide inhibits the reaction [Cadmium Chloride results in decreased expression of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone affects the localization of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone binds to AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone promotes the reaction [AR protein binds to MYC enhancer]]; bicalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of AR mRNA]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of and results in increased phosphorylation of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; bicalutamide inhibits the reaction [Estradiol results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [Estradiol results in increased activity of AR protein]; bicalutamide inhibits the reaction [Fludrocortisone results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [Flutamide results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [laxogenin analog results in increased activity of AR protein]; bicalutamide inhibits the reaction [Metribolone results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [Metribolone results in increased activity of AR protein]; bicalutamide inhibits the reaction [Metribolone results in increased folding of and results in increased stability of AR protein]; bicalutamide inhibits the reaction [OSM protein results in increased activity of AR protein]; bicalutamide inhibits the reaction [Sirolimus results in increased activity of AR protein]; bicalutamide inhibits the reaction [Testosterone results in increased activity of AR protein]; bicalutamide promotes the reaction [AR protein binds to KLK3 promoter]; bicalutamide promotes the reaction [AR protein binds to NCOR2 protein]; bicalutamide promotes the reaction [Niclosamide inhibits the reaction [AR protein binds to KLK3 promoter]]; bicalutamide promotes the reaction [Niclosamide results in decreased expression of AR protein alternative form]; bicalutamide promotes the reaction [Niclosamide results in decreased expression of AR protein]; methoxyacetic acid inhibits the reaction [bicalutamide inhibits the reaction [Testosterone results in increased activity of AR protein]]; mibolerone inhibits the reaction [bicalutamide results in increased expression of AR protein]; Resveratrol promotes the reaction [bicalutamide results in decreased activity of AR protein] | PMID:10053169 PMID:11751618 PMID:11956172 PMID:11981028 PMID:12114440 PMID:12730620 PMID:12970580 PMID:15171712 PMID:15336702 PMID:15994348 PMID:16266977 PMID:16877366 PMID:17606915 PMID:17723170 PMID:17804755 PMID:18324645 PMID:18324785 PMID:18486176 PMID:18487222 PMID:18776922 PMID:18922931 PMID:19359544 PMID:20729295 PMID:21036700 PMID:21308717 PMID:21506597 PMID:23562765 PMID:23603339 PMID:24323034 PMID:24759320 PMID:25752796 PMID:26867867 PMID:27473015 PMID:27720946 PMID:28500234 PMID:28757136 PMID:29383186 PMID:29427707 PMID:33049310 PMID:33207735 PMID:35344071 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |